Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

Approvals/CIMA-AEMPS/DUVYZAT 8,86 MG/ML SUSPENSION ORAL

Approved

STANDARD

DUVYZAT 8,86 MG/ML SUSPENSION ORAL

Italfarmaco S.P.A.🇪🇸 Spanish Agency of Medicines and Medical Devices

Approval Date: Jul 29, 2025
Approval ID: ec268dccaa7d0620
Company: Italfarmaco S.P.A.
Type: Standard

Approval Details

Approval Id: ec268dccaa7d0620
Drug Cima Aemps Name: DUVYZAT 8,86 MG/ML SUSPENSION ORAL
Register Number: 1251930001
Holder Company Name: Italfarmaco S.P.A.
Marketing Company Name: Italfarmaco S.A.
Marketing Company Detail Path: /organization/italfarmaco-s-a
Authorization Date: 2025-07-29
Dosage Form: SUSPENSIÓN ORAL
Dose: 8,86 mg/ml
Route Of Administration: VÍA ORAL
Prescription Type: Diagnóstico Hospitalario
Commercialized: Yes
Company Name: Italfarmaco S.P.A.
Company Detail Path: /organization/italfarmaco-s-a

Company Information

Pharmaceutical Company Name: Italfarmaco S A
Country Name: Chile
City Name: santiago,santiago,country_cl
Address: Encomenderos 161 3-B

Approved

Quick Info

Agency

CIMA-AEMPS

Country

🇪🇸

Approval Date

Jul 29, 2025

Approval ID

ec268dccaa7d0620

Type

Standard

Back to CIMA-AEMPS Approvals

DUVYZAT 8,86 MG/ML SUSPENSION ORAL - CIMA-AEMPS Drug Approval Details